Wednesday, February 17, 2021 NIH Launches Study to Evaluate Remdesivir for Treating COVID-19 in Pregnancy A new study will evaluate the effects of remdesivir in hospitalized pregnant women who have been prescribed the drug to treat COVID-19. Called IMPAACT 2032, the study aims to determine how pregnant women metabolize remdesivir and whether there are any side effects. The study will compare the effects of remdesivir in pregnant women and non-pregnant women of childbearing potential who are hospitalized with COVID-19. IMPAACT 2032 is supported by NIAID, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health. It is conducted by the NIH-funded International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107